Sitryx Therapeutics Ltd. has disclosed 2-methylene-4-oxo-butanoic acid derivative compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.

An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients. The research could provide an explanation for the ongoing interstitial lung disease and fibrosis seen in patients who were hospitalized with severe COVID-19, and also point to neutrophils as a specific therapeutic target.

Medshine Discovery Inc. has identified imidazopyridine compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of autoimmune diseases.

New research presented by the University of Michigan revealed groundbreaking results for Certa Therapeutics Pty Ltd.’s lead candidate, FT-011, for serious inflammatory and fibrotic diseases.

New research presented by the University of Michigan revealed groundbreaking results for Certa Therapeutics Pty Ltd.’s lead candidate, FT-011, for serious inflammatory and fibrotic diseases. The results of a chronic kidney disease study presented at the American Society of Nephrology meeting on Nov. 4 concluded that FT-011 reverses the activation of molecular markers associated with fibrosis.

Based on an analysis of critical transcription factors, researchers have stratified rheumatoid arthritis (RA) into two subtypes where gene expression was driven by RAR-α or TGF-β, respectively. The findings, published in Nature Communications on Oct. 20, 2022, by researchers from the University of California, San Diego, give new insights into factors that affect the treatment response in RA, and could point to novel treatment strategies.